Asia FX steady as Fed, BOJ rate decisions loom; US-China talks in focus
CARLSBAD, Calif. - Carlsmed, Inc., a medical technology company focused on AI-enabled personalized spine surgery solutions, has priced its initial public offering at $15.00 per share. The company is offering 6,700,000 shares of common stock, which are expected to begin trading today on The Nasdaq Global Select Market under the ticker symbol "CARL." The offering values Carlsmed at a market capitalization of approximately $398 million.
The offering is expected to close on Thursday, subject to customary closing conditions. Carlsmed anticipates gross proceeds of approximately $100.5 million from the offering, before deducting underwriting discounts, commissions, and other expenses. According to InvestingPro data, the company maintains strong liquidity with a current ratio of 6.48, though it reported an EBITDA of -$24.37 million in the last twelve months.
The company has granted the underwriters a 30-day option to purchase up to an additional 1,005,000 shares at the initial public offering price, less underwriting discounts and commissions.
BofA Securities, Goldman Sachs & Co. LLC, and Piper Sandler are serving as joint lead book-running managers for the offering, while Truist Securities and BTIG are acting as joint book-runners.
Carlsmed describes itself as a commercial-stage company that develops personalized spine surgery solutions. The U.S. Securities and Exchange Commission declared the registration statement for these securities effective on July 22, 2025.
The information in this article is based on a press release statement from the company.
In other recent news, Carlsmed, Inc. has announced the launch of its initial public offering (IPO), planning to offer 6,700,000 shares of common stock. The company expects to price these shares between $14.00 and $16.00 each. Additionally, underwriters have been given a 30-day option to purchase up to an extra 1,005,000 shares at the initial offering price, minus underwriting discounts and commissions. This development marks a significant step for Carlsmed as it enters the public market. The announcement highlights the company’s focus on expanding its financial base through public investment. Investors will be closely watching how the market responds to this offering. The pricing of the shares will be crucial in determining the initial success of the IPO.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.